ARTICLE | Company News

Biocon, CIMAB expand JV

June 22, 2004 7:00 AM UTC

Biocon Biopharmaceuticals, a joint venture between Biocon (NSE:BIOCONEQ) and CIMAB (Havana, Cuba), has licensed five compounds from CIMAB. These include: h-T1, a humanized monoclonal antibody against CD6 to treat T cell lymphoma, rheumatoid arthritis (RA) and psoriasis; q-T3, a chimeric antibody against CD3 for use as an immunosuppressant in organ transplant patients; an epidermal growth factor (EGF) cancer vaccine; a transforming growth factor (TGF) alpha cancer vaccine; and a HER-1 cancer vaccine. The JV has global marketing rights to q-T3 and h-T1 outside Latin America. It has rights to market h- R3 and the cancer vaccines in South Asia. ...